Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 7:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hyperinflation Clear all
Completed Not applicable Interventional Results available

Sustainability of Pulmonary Rehab Gains

NCT02241733
View directory record Official record
Conditions
COPD
Interventions
Breathing retraining plus exercise, Exercise only
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Oct 19, 2026, 7:45 PM EDT
Withdrawn Phase 2 Interventional

Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension

NCT02108743
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension.
Interventions
Albuterol., Normal saline placebo
Drug
Lead sponsor
American Medical Association Foundation
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Oct 19, 2026, 7:45 PM EDT
Terminated Phase 3 Interventional

Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE)

NCT01449292
View directory record Official record
Conditions
Pulmonary Emphysema
Interventions
Treatment plus Optimal Medical Therapy, Optimal Medical Therapy
Device · Other
Lead sponsor
Aeris Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Oct 19, 2026, 7:45 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease

NCT01072396
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
11
States / cities
Birmingham, Alabama • Jasper, Alabama • Torrance, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2013 · Synced Oct 19, 2026, 7:45 PM EDT
Recruiting Not applicable Interventional

A Multi Center Study Testing a New Implant for Adults With Severe Emphysema

NCT07119229
View directory record Official record
Conditions
Emphysema or COPD, Emphysema, COPD
Interventions
Implantable Artificial Bronchus
Device
Lead sponsor
Pulmair Medical, Inc.
Industry
Eligibility
22 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 19, 2026, 7:45 PM EDT
Completed Phase 4 Interventional Results available

Phase IV O2 Consumption Study in COPD Patients.

NCT02533505
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol, Matching Placebo pMDI 160/4.5 μg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Hartford, Connecticut • Boston, Massachusetts • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Oct 19, 2026, 7:45 PM EDT
Completed Not applicable Interventional

Abdominal Functional Electrical Stimulation to Reduce Hyperinflation in Chronic Obstructive Pulmonary Disease Patients

NCT02035228
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Abdominal Stimulation - low / early, Abdominal stimulation - low/late, Abdominal Stimulation - low/full, Abdominal stimulation - med/early, Abdominal stimulation - med/late, Abdominal Stimulation - med/full, Abdominal Stimulation - high/early, Abdominal Stimulation - high/late, Abdominal Stimulation - high/full
Device
Lead sponsor
Liberate Medical
Industry
Eligibility
40 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 19, 2026, 7:45 PM EDT
Completed Phase 3 Interventional Results available

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.

NCT01533935
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo, tiotropium + Olodaterol, Tiotropium, Olodaterol, Respimat
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 75 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Phoenix, Arizona • Austell, Georgia • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2015 · Synced Oct 19, 2026, 7:45 PM EDT
Completed Phase 2 Interventional

Inhaled Iloprost, Dynamic Hyperinflation, and Oxidative Stress in COPD Patients

NCT01941225
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Inhaled iloprost 5.0 mcg, Placebo
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
40 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 19, 2026, 7:45 PM EDT
Terminated Phase 4 Interventional Results available

Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo

NCT01760304
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Budesonide / Formoterol, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 19, 2026, 7:45 PM EDT
Completed Phase 3 Interventional Results available

A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00500318
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Aclidinium Bromide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
42
States / cities
Jasper, Alabama • Phoenix, Arizona • Long Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 19, 2026, 7:45 PM EDT
Completed Phase 4 Interventional

Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients

NCT03611699
View directory record Official record
Conditions
COPD
Interventions
Umeclidinium / Vilanterol Dry Powder Inhaler, Placebo
Drug
Lead sponsor
Gary L. Pierce
Other
Eligibility
30 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 19, 2026, 7:45 PM EDT
Recruiting Not applicable Interventional

Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3

NCT06891755
View directory record Official record
Conditions
COPD, Emphysema
Interventions
Apreo BREATHE Airway Scaffold, Optimal Medical Management (OMM)
Device · Other
Lead sponsor
Apreo Health, Inc.
Industry
Eligibility
40 Years to 84 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
18
States / cities
Birmingham, Alabama • Gilbert, Arizona • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 19, 2026, 7:45 PM EDT
Recruiting Not applicable Interventional

Hyperinflation Respiratory Therapies in Cardiac Surgery Patients

NCT04164173
View directory record Official record
Conditions
Pulmonary Disease, Postoperative Complications
Interventions
EzPAP, Metaneb, Intermittent Positive Pressure Breathing (IPPB)
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 19, 2026, 7:45 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Reducing Dynamic Hyperinflation Through Breathing Retraining

NCT01009099
View directory record Official record
Conditions
Pulmonary Disease, COPD
Interventions
breathing retraining, exercise training
Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years to 85 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 18, 2015 · Synced Oct 19, 2026, 7:45 PM EDT
Recruiting Not applicable Interventional

An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema

NCT06035120
View directory record Official record
Conditions
Emphysema, Pulmonary, Emphysema or COPD
Interventions
AeriSeal System
Device
Lead sponsor
Pulmonx Corporation
Industry
Eligibility
40 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
20
States / cities
Phoenix, Arizona • Loveland, Colorado • Hartford, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 19, 2026, 7:45 PM EDT
Completed No phase listed Observational

Electrical Impedance Imaging of Patients on Mechanical Ventilation

NCT02232841
View directory record Official record
Conditions
Pneumothorax, Pulmonary Contusion, Pleural Effusion, Pulmonary Edema, Atelectasis, Hyperinflation, Emphysema, Acute Respiratory Distress Syndrome
Interventions
Mechanical Ventilation, CT Scan
Device
Lead sponsor
Colorado State University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Loveland, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 19, 2026, 7:45 PM EDT
Completed Phase 3 Interventional Results available

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients

NCT01533922
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo, Tiotropium, Olodaterol, Tiotropium + Olodaterol, Respimat
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 75 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
8
States / cities
Torrance, California • Hartford, Connecticut • Livonia, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2015 · Synced Oct 19, 2026, 7:45 PM EDT
Completed No phase listed Observational

4D Medical X-ray Velocimetry for Bronchoscopic Lung Volume Reduction Targeting

NCT04786171
View directory record Official record
Conditions
Copd, Emphysema, Hyperinflation
Interventions
4D X-ray Velocimetry
Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 19, 2026, 7:45 PM EDT
Completed Not applicable Interventional

Device-guided Breathing for Shortness of Breath in COPD

NCT01286181
View directory record Official record
Conditions
COPD, Dyspnea, Hyperinflation
Interventions
Twice daily practice of device-guided slow breathing.
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 19, 2026, 7:45 PM EDT
Completed Phase 4 Interventional Results available

A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease.

NCT04155047
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Glyocopyrrolate Inhalation Solution administered by Magnair, Placebo administered by Magnair
Combination Product · Drug
Lead sponsor
Sunovion Respiratory Development Inc.
Industry
Eligibility
40 Years to 99 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 19, 2026, 7:45 PM EDT
Completed Phase 3 Interventional

The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)

NCT00108823
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD
Interventions
Roflumilast
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
10
States / cities
Cities in California, California • Cities in Colorado, Colorado • Cities in Florida, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 19, 2026, 7:45 PM EDT
Not listed Phase 3 Interventional

EASE Trial: Exhale Airway Stents for Emphysema

NCT00391612
View directory record Official record
Conditions
Emphysema
Interventions
Exhale® Drug-Eluting Stent, Sham control
Device
Lead sponsor
Broncus Technologies
Industry
Eligibility
35 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
26
States / cities
Phoenix, Arizona • Fresno, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2011 · Synced Oct 19, 2026, 7:45 PM EDT
Completed Phase 4 Interventional Results available

The Effect of BEVESPI AEROSPHERE ® Therapy on Exercise Tolerance in COPD

NCT03081156
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Glycopyrrolate / Formoterol Inhaler vs Placebo Inhaler
Drug
Lead sponsor
William Stringer, md
Other
Eligibility
40 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 19, 2026, 7:45 PM EDT